189 related articles for article (PubMed ID: 26472316)
21. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
[TBL] [Abstract][Full Text] [Related]
23. Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.
Hof SV; Delaney AR; Tekatli H; Twisk J; Slotman BJ; Senan S; Dahele M; Verbakel WFAR
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):259-267. PubMed ID: 30114461
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
25. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
[TBL] [Abstract][Full Text] [Related]
26. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
Tekatli H; Palacios MA; Schneiders FL; Haasbeek CJA; Slotman BJ; Lagerwaard FJ; Senan S
Radiother Oncol; 2023 Oct; 187():109823. PubMed ID: 37516364
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
[TBL] [Abstract][Full Text] [Related]
28. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
29. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
30. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
Verstegen NE; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Radiother Oncol; 2011 Nov; 101(2):250-4. PubMed ID: 22056535
[TBL] [Abstract][Full Text] [Related]
32. Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies.
Giglioli FR; Strigari L; Ragona R; Borzì GR; Cagni E; Carbonini C; Clemente S; Consorti R; El Gawhary R; Esposito M; Falco MD; Fedele D; Fiandra C; Frassanito MC; Landoni V; Loi G; Lorenzini E; Malisan MR; Marino C; Menghi E; Nardiello B; Nigro R; Oliviero C; Pastore G; Quattrocchi M; Ruggieri R; Redaelli I; Reggiori G; Russo S; Villaggi E; Casati M; Mancosu P
Phys Med; 2016 Apr; 32(4):600-6. PubMed ID: 27061871
[TBL] [Abstract][Full Text] [Related]
33. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
36. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.
Senthi S; Haasbeek CJ; Slotman BJ; Senan S
Radiother Oncol; 2013 Mar; 106(3):276-82. PubMed ID: 23462705
[TBL] [Abstract][Full Text] [Related]
40. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
